#1NVIDIA ENTERING THE AI HEALTHCARE ERA JP Morgan 2021 | Kimberly Powell VP, GM Healthcare#2SAFE HARBOR Forward-Looking Statements Except for the historical information contained herein, certain matters in this presentation including, but not limited to, statements as to: the performance, benefits, abilities, availability and impact of our products and technologies; TAMS, market sizes and market spend; artificial intelligence being the most powerful technology force of our time; how artificial intelligence is used; Cambridge-1; the adoption of our technologies; Al healthcare startups; enabling the Al healthcare era; our markets; and our growth and growth drivers are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements and any other forward-looking statements that go beyond historical facts that are made in this presentation are subject to risks and uncertainties that may cause actual results to differ materially. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners' products; design, manufacturing or software defects; changes in consumer preferences and demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems and other factors. NVIDIA has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks and uncertainties, and you should not rely upon the forward-looking statements as predictions of future events. The future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although NVIDIA believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee that future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. Except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances. For a complete discussion of factors that could materially affect our financial results and operations, please refer to the reports we file from time to time with the SEC, including our Annual Report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports we file with the SEC are posted on our website and are available from NVIDIA without charge.#3DEK ADVANCING DRUG DISCOVERY THROUGH COMPUTING $1.25T Industry | $2B R&D per Drug | 12 Years Development | 90% Failure Rate GENOMICS Disease Target STRUCTURE Literature Chemical Compounds SEARCH DOCKING and urinary symptoms A preliminary diagnosis of was established. Other causes of lavar e possible but less likely. The patient was hypotensive with a blood pressure ef 8040 Serum lactate Abolus of IV was administered (1.5L) but the patient remained hypotensive Our colleagues from ICU were consulted An arterial line was inserted for hemodynamic monitoring Hemodynamics were supported with levophed and crystalloids NT Pipta was started after blood and urine cultures were drawn. After 12 hours was elevated mat 6.1. serum lactate had normalized and hemodynamics had stablized Blood cultures were positive for E Call that was sensitive to ipad down to NLP SIMULATION Real World Data Drug Candidate IMAGING#4GENETIC VARIANT DETECTION Deep Learning Variant Calling NVIDIA Clara & Google DeepVariant VIRTUAL DRUG SCREENING Docking 40B Compounds UBC DeepDocking ARTIFICIAL INTELLIGENCE - THE MOST POWERFUL TECHNOLOGY FORCE OF OUR TIME PROTEIN STRUCTURE PREDICTION Experimental Accuracy Google AlphaFold CYS 107 DRUG DISCOVERY 1,000X Faster Simulations Caltech OrbNet A remained hyp was inserted Su An arterial line TREATMENT Piptazo TREATME Hemodynamics were supported with levop crystalloids TREATMENT blood and urine cultures TEST were dr had normalized BIOMEDICAL & CLINICAL NLP State-of-the-Art Language Model NVIDIA BioMegatron BioBERT COMPUTATIONAL MICROSCOPE Atomic Molecular Simulation UCSD NAMD & ANL DeepDrive MD Experimental Accuracy | Prediction | Simulation 10 5 0 COMPUTATIONAL DEMAND FOR AI DRIVEN DRUG DISCOVERY (petaFLOPS per organization)* 2016 2018 TOTAL HPC+AI 2020 Al HPC CV ML NLP AlphaFold DeepVariant Generative Models *Source: NVIDIA estimated - assumes a computational pipeline that identifies 10 disease targets, screens 1M compounds per target (inc. virtual & HCS) and 500 simulations per target#5MIXI များ ARTIFICIAL INTELLIGENCE SOFTWARE THAT WRITES SOFTWARE Domain Specific: Data, Algorithms, Skills $3 Digital Health Data Hello DEVELOP AI MODEL Algorithms & Compute DEPLOY RADIOLOGY PATIENT MONITORING PATHOLOGY GENOMICS Automated Skills SURGICAL DECISION SUPPORT#6MIXI များ $3 NVIDIA CLARA DOMAIN SPECIFIC COMPUTATIONAL PLATFORM FOR HEALTHCARE Digital Health Data Hello PRE-TRAINED MODELS Chemistry Genomics Imaging Biomedical NLP FEDERATED LEARNING CLOUD TRAINING FRAMEWORK DATA CENTER SCALABLE DEPLOYMENT NVIDIA COMPUTING PLATFORMS EDGE ΜΟΝΑΙ PyTorch TRITON Inference Server Algorithms & Compute EMBEDDED 3= RADIOLOGY PATIENT MONITORING PATHOLOGY GENOMICS Automated Skills SURGICAL DECISION SUPPORT#7GENOMICS NVIDIA CLARA COMPUTATIONAL PLATFORM FOR HEALTHCARE NLP Fever pyelonephritis were possible but less likely. The patient was hypotensive initial assessment resT with a blood pressure TEST of 30/40. Serum lactate was elevated Pat 6.1. and urinary symptoms Apreliminary diagnosis of was established. Other causes of lever A bolus of IV fluid was administered (1.5L) but the patient remained hypotensive PROBLEM. Our colleagues from ICU were consulted. An arterial line TREMENT was inserted for hemodynamic monitoring Te Hemodynamics were supported with levophed TREATMENT and crystalloids TREATMENT Piplazo was started after blood and urine cultures TEST were drawn. After 12 hours serum lactate TEST had normalized and hemodynamics TET had stabilized. Blood cultures all antibiotics The patient was stepped down to oral ciprofloxacin TREATMENT to complete a total 14 day course of antibiotics TREATMENT Fever and urinary symptom pyelonephritis POLE was established. O were possible but less likely. The patient was initial assessment with a blood pres Serum lactate TT was elevated PROBLE A bolus of IV fluid TREATMENT was administe were positive for E Coll PRO that was sensitive to A preliminan, diagnorie 2019 5X IMAGING 125K Downloads 2020 INSTRUMENTS AAC800 HYPERFINE 1,000+ NVIDIA Inception Al Healthcare Startups CONVERSATIONAL AI ===== 500K NVIDIA GPU Instruments Deployed DRUG DISCOVERY#8GENOMICS Clara Parabricks, RAPIDS INTRODUCING NVIDIA CLARA DISCOVERY Al Computational Drug Discovery: Frameworks, Applications, Algorithms Disease Target STRUCTURE CryoSPARC, Relion, Alpha Fold Literature Chemical Compounds SEARCH RAPIDS DOCKING RAPIDS and urinary symptoms Serum lactate Abolus of IV remained hypotensive mos A preliminary diagnosis of pyelonephritis possible but less likely. The patient was hypotensive on with a blood pressure of 80/40 was elevated mat 6.1. was established. Other causes of lever was administered (1.5L) but the patient Our colleagues from ICU were consuted An arterial line was inserted for hemodynamic monitoring Hemodynamics were supported with levophod and crystalloids NT Piptazo was started after blood and urine cultures were drawn. After 12 ho serum lactate had nomalized and hemodynamics had stablized Blood cultures were positive for EColl NLP that was sensitive to pad down to BioMegatron, BioBERT SIMULATION NAMD, VMD, OpenMM, MELD Real World Data Drug Candidate IMAGING Clara Imaging, MONAI#9AI DRIVEN DRUG DISCOVERY World Leaders Using GPU Accelerated Computing & Al for Drug Discovery GENETICS Disease Target REGENERON" GENETICS CENTER STRUCTURA TA BIOTECHNOLOGY STRUCTURE Literature Chemical Compounds RELAY THERAPEUTICS SEARCH Atomwise SAMPLING VYASA NLP SCHRÖDINGER. SIMULATION Real World Data Above organizations focus is broader than the GPU reference applications shown Drug Candidate Recursion IMAGING#10Ee AstraZeneca HEALTHCARE & LIFE SCIENCE RESEARCH CAMBRIDGE-1 AI SUPERCOMPUTER Computational Instrument for Al Healthcare NHS Guy's and St Thomas' NHS Foundation Trust gsk LARGE-SCALE AI & DATA SCIENCE RESEARCH College LONDON Oxford 80 NVIDIA DGX A100 | 400 PETAFLOPS AI COMPUTE| UK'S FASTEST AI SUPERCOMPUTER | WORLD'S TOP 5 GREEN SUPERCOMPUTER COLLABORATION WITH UK INDUSTRY, UNIVERSITIES, STARTUPS NANOPORE Technologies EDUCATE FUTURE AI PRACTITIONERS#11$5.5 B $3.5 B $1.5 B AI HEALTHCARE STARTUPS MAKE HISTORY IN 2020 Record Year of Funding | Dozens of Industry Firsts Healthcare Al Startup Funding by Quarter* 2019 2020** *Source: CBInsights: State Of Healthcare Q3'20 Report: Investment & Sector Trends to Watch ** Estimated Al Training | Early Access Tech Integration | Industry Alliance NVIDIA. 273 2017 INCEPTION PROGRAM 1,095 2020 Digital Health babylon Curai nference 'T'EMPUS VYASA ♥依图|YITU Drug Imaging & Instruments Discovery ACTIV SURGICAL Caption Health HURON Digital Pathology HYPERFINE *Quantib Viz.ai Atomwise healx OWKIN Recursion UNLEARN#1220,000 10,000 0 Al Papers in PubMed (Machine Learning or Deep Learning) 2010 AI IN THE PRACTICE OF MEDICINE Healthcare Spend $8T | Aging & Growing Population | Chronic Disease | Prevention 2015 2020 Al Healthcare Research DEVELOP AI MODEL DEPLOY Continuous Learning -> Software Defined RADIOLOGY PATIENT MONITORING PATHOLOGY GENOMICS Al Skills SURGICAL DECISION SUPPORT#13SOFTWARE DEFINED AI INSTRUMENT REVOLUTION Sensing | Predicting | Assisting ERKE Acqu COMPUTE PLATFORMS CLOUD NVIDIA EDGE DATA CENTER EMBEDDED PASSIO 0/ HYPERF#14ANNOUNCING OXFORD NANOPORE TECHNOLOGIES ADOPTS NVIDIA DGX FOR ULTRA-HIGH THROUGHPUT PROMETHION Real-Time Sequencing, Al Driven Accuracy High Throughput up to 10 Terabases | 100 Human Genomes per Run Deep Learning Basecaller "Bonito" 98.3% Raw Accuracy Al Driven Single Nucleotide Variant Calling 99.9% Accuracy COVID-19 Testing | Viral Sequencing Human Genetics | Cancer Research O Oxford NVIDIA ONANOPORE Technologies 100% 90% 80% 2016 AI SEQUENCING ACCURACY Deep Learning 2017 2018 PromethION Models & Training 2019 2020 LLLLLL DOX STATION NVIDIA#15TEE AstraZeneca ENABLING THE AI HEALTHCARE ERA NVIDIA Clara Computational Platform for Healthcare NHS Guy's and St Thomas' NHS Foundation Trust NVIDIA Ecosystem Innovators in Al Drug Discovery Atomwise REGENERON" GENETICS CENTER Recursion RELAY SCHRÖDINGER. STRUCTURA T BIOTECHNOLOGY VYASA gsk College LONDON NVIDIA Inception 1000+ Member Startup Accelerator NVIDIA. INCEPTION PROGRAM Oxford NANOPORE NVIDA Software Defined Al Instrument Revolution Z NANOPORE Technologies#16NVIDIA®